El Dipòsit Digital ha actualitzat el programari. Contacteu amb dipositdigital@ub.edu per informar de qualsevol incidència.

 

White matter alterations in Alzheimer’s disease without concomitant pathologies

dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)
dc.contributor.authorAndrés Benito, Pol
dc.date.accessioned2021-02-25T13:40:38Z
dc.date.available2021-02-25T13:40:38Z
dc.date.issued2020-05-01
dc.date.updated2021-02-18T13:05:19Z
dc.description.abstractAims: Most individuals with AD neuropathological changes have co-morbidities which have an impact on the integrity of the WM. This study analyses oligodendrocyte and myelin markers in the frontal WM in a series of AD cases without clinical or pathological co-morbidities. Methods: From a consecutive autopsy series, 206 cases had neuropathological changes of AD; among them, only 33 were AD without co-morbidities. WM alterations were first evaluated in coronal sections of the frontal lobe in every case. Then, RT-qPCR and immunohistochemistry were carried out in the frontal WM of AD cases without co-morbidities to analyse the expression of selected oligodendrocyte and myelin markers. Results: WM demyelination was more marked in AD with co-morbidities when compared with AD cases without co-morbidities. Regarding the later, mRNA expression levels of MBP, PLP1, CNP, MAG, MAL, MOG and MOBP were preserved at stages I-II/0-A when compared with middle-aged (MA) individuals, but significantly decreased at stages III-IV/0-C. This was accompanied by reduced expression of NG2 and PDGFRA mRNA, reduced numbers of NG2-, Olig2- and HDAC2-immunoreactive cells and reduced glucose transporter immunoreactivity. Partial recovery of some of these markers occurred at stages V-VI/B-C. Conclusions: The present observations demonstrate that co-morbidities have an impact on WM integrity in the elderly and in AD, and that early alterations in oligodendrocytes and transcription of genes linked to myelin proteins in WM occur in AD cases without co-morbidities. These are followed by partial recovery attempts at advanced stages. These observations suggest that oligodendrocytopathy is part of AD.
dc.format.extent19 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid32255227
dc.identifier.urihttps://hdl.handle.net/2445/174348
dc.language.isoeng
dc.publisherWiley
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1111/nan.12618
dc.relation.ispartofNeuropathology and Applied Neurobiology, 2020, vol. 46, num. 7, p. 654-672
dc.relation.urihttps://doi.org/10.1111/nan.12618
dc.rightscc by (c) Ferrer et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationMalaltia d'Alzheimer
dc.subject.classificationMielina
dc.subject.otherAlzheimer's disease
dc.subject.otherMyelin sheath
dc.titleWhite matter alterations in Alzheimer’s disease without concomitant pathologies
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
nan.12618.pdf
Mida:
1.12 MB
Format:
Adobe Portable Document Format